On the one hand, step therapy protocols provide insurers with a way to negotiate lower drug costs. On the other, step therapy is considered an onerous condition of reimbursement, particularly given its fail-first implications.
Drug Formulary Managers’ Use Of Step Therapy Can Lead To Sub-Optimal Outcomes
